Cited by 189Proteoglycans and glycosaminoglycans researchProtease and Inhibitor MechanismsTGF-β signaling in diseases

The DOI matches its Crossref record; 115 of the 115 references it cites were found in a registry or an index.

The heparanase/syndecan‐1 axis in cancer: mechanisms and therapies

Open access

Ramani, Vishnu C., Purushothaman, Anurag, Stewart, Mark D., Thompson, Camilla A., Vlodavsky, Israel, Au, Jessie L‐S., Sanderson, Ralph D.·2013·The FEBS Journal

DOI 10.1111/febs.12168PMC PMC3651779

Open this paper in CoChat — free account

Abstract

Heparanase is an endoglucuronidase that cleaves heparan sulfate chains of proteoglycans. In many malignancies, high heparanase expression and activity correlate with an aggressive tumour phenotype. A major consequence of heparanase action in cancer is a robust up‐regulation of growth factor expression and increased shedding of syndecan‐1 (a transmembrane heparan sulfate proteoglycan). Substantial evidence indicates that heparanase and syndecan‐1 work together to drive growth factor signalling and regulate cell behaviours that enhance tumour growth, dissemination, angiogenesis and osteolysis. Preclinical and clinical studies have demonstrated that therapies targeting the heparanase/syndecan‐1 axis hold promise for blocking the aggressive behaviour of cancer.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1111/febs.12168

Cites

115 of 115 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells
Valadi, H., Ekström, K., Bossios, A., Sjöstrand, M., Lee, J. J., & Lötvall, J. O. (2007) · Nature Cell Biology · doi:10.1038/ncb1596 · Cited by 12,834
Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET
Peinado, H., Alečković, M., Lavotshkin, S., Matei, I., Costa-Silva, B., Moreno-Bueno, G., Hergueta-Redondo, M., Williams, C., García-Santos, G., Ghajar, C. M., et al. (2012) · Nature Medicine · doi:10.1038/nm.2753 · Cited by 3,715
Requirement of Vascular Integrin α v β 3 for Angiogenesis
Brooks, P. C., Clark, R. A. F., & Cheresh, D. A. (1994) · Science · doi:10.1126/science.7512751 · Cited by 3,020
Functions of Cell Surface Heparan Sulfate Proteoglycans
Bernfield, M. R., Götte, M., Park, P. W., Reizes, O., Fitzgerald, M. L., Lincecum, J. M., & Zako, M. (1999) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.68.1.729 · Cited by 2,722
Met, metastasis, motility and more
Birchmeier, C., Birchmeier, W., Gherardi, E., & Woude, G. F. V. (2003) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1261 · Cited by 2,652
Syndecan–syntenin–ALIX regulates the biogenesis of exosomes
Baietti, M. F., Zhang, Z., Mortier, E., Melchior, A., Degeest, G., Geeraerts, A., Ivarsson, Y., Depoortere, F., Coomans, C., Vermeiren, E., et al. (2012) · Nature Cell Biology · doi:10.1038/ncb2502 · Cited by 1,899
Exosome Secretion: Molecular Mechanisms and Roles in Immune Responses
Bobrie, A., Colombo, M., Raposo, G., & Théry, C. (2011) · Traffic · doi:10.1111/j.1600-0854.2011.01225.x · Cited by 1,148
The pulmonary endothelial glycocalyx regulates neutrophil adhesion and lung injury during experimental sepsis
Schmidt, E. P., Yang, Y., Janssen, W. J., Gandjeva, A., Perez, M. J., Barthel, L., Zemans, R. L., Bowman, J. C., Koyanagi, D., Yunt, Z. X., et al. (2012) · Nature Medicine · doi:10.1038/nm.2843 · Cited by 842
Microvesicles derived from activated platelets induce metastasis and angiogenesis in lung cancer
Janowska‐Wieczorek, A., Wysoczynski, M., Kijowski, J., Marquez‐Curtis, L. A., Machaliński, B., Ratajczak, J., & Ratajczak, M. Z. (2004) · International Journal of Cancer · doi:10.1002/ijc.20657 · Cited by 781
Large-scale proteomics and phosphoproteomics of urinary exosomes
Gonzales, P. A., Pisitkun, T., Hoffert, J. D., Tchapyjnikov, D., Star, R. A., Kleta, R., Wang, N. S., & Knepper, M. A. (2009) · Journal of the American Society of Nephrology · doi:10.1681/asn.2008040406 · Cited by 727

Show all 115 references

Research works printed but not linked: 1

10.1042/0264-6021:3370471 · DOI

Sorted by citations

Extracellular matrix structure
Theocharis, A. D., Skandalis, S. S., Gialeli, C., & Karamanos, N. K. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.11.001 · Cited by 2,598
Tumor microenvironment complexity and therapeutic implications at a glance
Baghban, R., Roshangar, L., Jahanban-Esfahlan, R., Seidi, K., Ebrahimi-Kalan, A., Jaymand, M., Kolahian, S., Javaheri, T., & Zare, P. (2020) · Cell Communication and Signaling · doi:10.1186/s12964-020-0530-4 · Cited by 1,784
“A number of preclinical and clinical findings have reported that targeting pathways and molecules involved in the formation of exosome can inhibit tumor progression, such as heparanase/syndecan-1 axis [182, 183] or syndecan heparan sulfate proteoglycans [179, 184] .”
Background
Extracellular matrix remodeling in tumor progression and immune escape: from mechanisms to treatments
Yuan, Z., Li, Y., Zhang, S., Wang, X., Dou, H., Yu, X., Zhang, Z., Yang, S., & Xiao, M. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01744-8 · Cited by 977
Exosome-Mediated Metastasis: From Epithelial–Mesenchymal Transition to Escape from Immunosurveillance
Syn, N. L. X., Wang, L., Sethi, G., Thiery, J. P., & Goh, B. C. (2016) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2016.04.006 · Cited by 484
TIMPs: versatile extracellular regulators in cancer
Jackson, H. W., Defamie, V., Waterhouse, P. D., & Khokha, R. (2016) · Nature reviews. Cancer · doi:10.1038/nrc.2016.115 · Cited by 454
Heparan Sulfate: Biosynthesis, Structure, and Function
Li, J.-P., & Kusche‐Gullberg, M. (2016) · International review of cytology · doi:10.1016/bs.ircmb.2016.02.009 · Cited by 312
Syndecans – key regulators of cell signaling and biological functions
Afratis, N. A., Nikitovic, D., Multhaupt, H. A. B., Theocharis, A. D., Couchman, J., & Karamanos, N. K. (2016) · FEBS Journal · doi:10.1111/febs.13940 · Cited by 292
Heparanase: From basic research to therapeutic applications in cancer and inflammation
Vlodavsky, I., Singh, P., Boyango, I., Gutter-Kapon, L., Elkin, M., Sanderson, R. D., & Ilan, N. (2016) · Drug Resistance Updates · doi:10.1016/j.drup.2016.10.001 · Cited by 244
Self-citation
Chemotherapy induces secretion of exosomes loaded with heparanase that degrades extracellular matrix and impacts tumor and host cell behavior
Bandari, S., Purushothaman, A., Ramani, V. C., Brinkley, G. J., Chandrashekar, D. S., Varambally, S., Mobley, J. A., Zhang, Y., Brown, E. E., Vlodavsky, I., et al. (2017) · Matrix Biology · doi:10.1016/j.matbio.2017.09.001 · Cited by 224
Self-citation
Exosomes: Small vesicles with big roles in cancer, vaccine development, and therapeutics
Thakur, A., Parra, D. C., Motallebnejad, P., Brocchi, M., & Chen, H. J. (2021) · Bioactive Materials · doi:10.1016/j.bioactmat.2021.08.029 · Cited by 224
Heparanase regulation of cancer, autophagy and inflammation: new mechanisms and targets for therapy
Sanderson, R. D., Elkin, M., Rapraeger, A. C., Ilan, N., & Vlodavsky, I. (2016) · FEBS Journal · doi:10.1111/febs.13932 · Cited by 216
Self-citation
Extracellular matrix component signaling in cancer
Multhaupt, H. A. B., Leitinger, B., Gullberg, D., & Couchman, J. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.10.013 · Cited by 197
The Role of Heparanase and Sulfatases in the Modification of Heparan Sulfate Proteoglycans within the Tumor Microenvironment and Opportunities for Novel Cancer Therapeutics
Hammond, E., Khurana, A., Shridhar, V., & Dredge, K. S. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00195 · Cited by 192
Syntenin and syndecan in the biogenesis of exosomes
Friand, V., David, G., & Zimmermann, P. (2015) · Biology of the Cell · doi:10.1111/boc.201500010 · Cited by 200
Roles of exosomes in the normal and diseased eye
Klingeborn, M., Dismuke, W. M., Rickman, C. B., & Stamer, W. D. (2017) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2017.04.004 · Cited by 186
Insights into the key roles of proteoglycans in breast cancer biology and translational medicine
Theocharis, A. D., Skandalis, S. S., Neill, T., Multhaupt, H. A. B., Hubo, M., Frey, H., Gopal, S., Gomes, A. M., Afratis, N. A., Lim, H. C., et al. (2015) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2015.03.006 · Cited by 162
Self-citation
Re-visiting the structure of heparin
Casu, B., Naggi, A., & Torri, G. (2014) · Carbohydrate Research · doi:10.1016/j.carres.2014.06.023 · Cited by 145
Emerging roles and therapeutic value of exosomes in cancer metastasis
Wu, M., Wang, G., Hu, W., Yao, Y., & Yu, X.-F. (2019) · Molecular Cancer · doi:10.1186/s12943-019-0964-8 · Cited by 140
Loss of Syndecan-1 Induces a Pro-inflammatory Phenotype in Endothelial Cells with a Dysregulated Response to Atheroprotective Flow
Voyvodic, P. L., Min, D., Liu, R., Williams, E. J., Chitalia, V. C., Dunn, A. K., & Baker, A. B. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.541573 · Cited by 145
Bioengineered heparins and heparan sulfates
Fu, L., Suflita, M., & Linhardt, R. J. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.11.002 · Cited by 138
Syndecan-1 and Its Expanding List of Contacts
Stepp, M. A., Pal‐Ghosh, S., Tadvalkar, G., & Pajoohesh‐Ganji, A. (2014) · Advances in Wound Care · doi:10.1089/wound.2014.0555 · Cited by 129
Fibroblast growth factors as tissue repair and regeneration therapeutics
Nunes, Q. M., Li, Y., Sun, C., Kinnunen, T. K., & Fernig, D. G. (2016) · PeerJ · doi:10.7717/peerj.1535 · Cited by 120
Heparanase: A Multitasking Protein Involved in Extracellular Matrix (ECM) Remodeling and Intracellular Events
Masola, V., Bellin, G., Gambaro, G., & Onisto, M. (2018) · Cells · doi:10.3390/cells7120236 · Cited by 119
Heparanase-induced shedding of syndecan-1/CD138 in myeloma and endothelial cells activates VEGFR2 and an invasive phenotype: prevention by novel synstatins
Jung, O., Trapp‐Stamborski, V., Purushothaman, A., Jin, H., Wang, H., Sanderson, R. D., & Rapraeger, A. C. (2016) · Oncogenesis · doi:10.1038/oncsis.2016.5 · Cited by 116
Self-citation
Ultrasensitive Immunoprofiling of Plasma Extracellular Vesicles Identifies Syndecan-1 as a Potential Tool for Minimally Invasive Diagnosis of Glioma
Chandran, V. I., Welinder, C., Månsson, A., Offer, S., Freyhult, E., Pernemalm, M., Lund, S. M., Pedersen, S., Lehtiö, J., Marko‐Varga, G., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2946 · Cited by 117
Proteoglycans in liver cancer
Baghy, K. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i1.379 · Cited by 118
Targeting Heparanase in Cancer: Inhibition by Synthetic, Chemically Modified, and Natural Compounds
Mohan, C. D., Hari, S., Preetham, H. D., Rangappa, S., Barash, U., Ilan, N., Nayak, S. C., Gupta, V. K., Basappa, B., Vlodavsky, I., et al. (2019) · iScience · doi:10.1016/j.isci.2019.04.034 · Cited by 109
Self-citation
The potential of heparanase as a therapeutic target in cancer
Pisano, C., Vlodavsky, I., Ilan, N., & Zunino, F. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.02.010 · Cited by 109
Self-citation
Role of tumor-derived exosomes in cancer metastasis
Wee, I. J. Y., Syn, N. L. X., Sethi, G., Goh, B. C., & Wang, L. (2018) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2018.10.004 · Cited by 107
Cell–matrix interactions: focus on proteoglycan–proteinase interplay and pharmacological targeting in cancer
Theocharis, A. D., Gialeli, C., Bouris, P., Giannopoulou, E., Skandalis, S. S., Aletras, A. J., Iozzo, R. V., & Karamanos, N. K. (2014) · FEBS Journal · doi:10.1111/febs.12927 · Cited by 101
Genotoxic Stress Induces Senescence-Associated ADAM10-Dependent Release of NKG2D MIC Ligands in Multiple Myeloma Cells
Zingoni, A., Cecere, F., Vulpis, E., Fionda, C., Molfetta, R., Soriani, A., Petrucci, M. T., Ricciardi, M. R., Fuerst, D., Amendola, M. G., et al. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1402643 · Cited by 100
Cross-talk between estradiol receptor and EGFR/IGF-IR signaling pathways in estrogen-responsive breast cancers: Focus on the role and impact of proteoglycans
Skandalis, S. S., Afratis, N. A., Smirlaki, G., Nikitovic, D., Theocharis, A. D., Tzanakakis, G. N., & Karamanos, N. K. (2013) · Matrix Biology · doi:10.1016/j.matbio.2013.09.002 · Cited by 100
Heparanase enhances myeloma progression via CXCL10 downregulation
Barash, U., Zohar, Y., Wildbaum, G., Beider, K., Nagler, A., Karin, N., Ilan, N., & Vlodavsky, I. (2014) · Leukemia · doi:10.1038/leu.2014.121 · Cited by 97
Self-citation
Syndecans as Modulators and Potential Pharmacological Targets in Cancer Progression
Barbouri, D., Afratis, N. A., Gialeli, C., Vynios, D. H., Theocharis, A. D., & Karamanos, N. K. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00004 · Cited by 101
miRNA-558 promotes tumorigenesis and aggressiveness of neuroblastoma cells through activating the transcription of heparanase
Qu, H., Zheng, L., Pu, J., Mei, H., Xiang, X., Zhao, X., Li, D., Li, S., Mao, L., Huang, K., et al. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddv018 · Cited by 91
Deconstructing breast cancer cell biology and the mechanisms of multidrug resistance
Videira, M., Reis, R. L., & Brito, M. A. (2014) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2014.07.011 · Cited by 93
Molecular and clinical profiles of syndecan-1 in solid and hematological cancer for prognosis and precision medicine
Akl, M. R., Nagpal, P., Ayoub, N. M., Prabhu, S. A., Gliksman, M., Tai, B., Hatipoglu, A., Goy, A. H., & Suh, K. S. (2015) · Oncotarget · doi:10.18632/oncotarget.4981 · Cited by 88
Glycosylation and Cancer: Moving Glycomics to the Forefront
Drake, R. R. (2015) · Advances in cancer research · doi:10.1016/bs.acr.2014.12.002 · Cited by 90
Role of Heparanase-Driven Inflammatory Cascade in Pathogenesis of Diabetic Nephropathy
Goldberg, R., Rubinstein, A. M., Gil, N., Hermano, E., Li, J., van der Vlag, J., Atzmon, R., Meirovitz, A., & Elkin, M. (2014) · Diabetes · doi:10.2337/db14-0001 · Cited by 85
Role of heparanase in tumor progression: Molecular aspects and therapeutic options
Masola, V., Zaza, G., Gambaro, G., Franchi, M., & Onisto, M. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.07.014 · Cited by 88
Targeting heparanase overcomes chemoresistance and diminishes relapse in myeloma
Ramani, V. C., Zhan, F., He, J., Barbieri, P., Noseda, A., Tricot, G. J. K., & Sanderson, R. D. (2015) · Oncotarget · doi:10.18632/oncotarget.6408 · Cited by 85
Self-citation
Chemotherapy induces expression and release of heparanase leading to changes associated with an aggressive tumor phenotype
Ramani, V. C., Vlodavsky, I., Ng, M., Zhang, Y., Barbieri, P., Noseda, A., & Sanderson, R. D. (2016) · Matrix Biology · doi:10.1016/j.matbio.2016.03.006 · Cited by 84
Self-citation
Growth differentiating factor 15 enhances the tumor-initiating and self-renewal potential of multiple myeloma cells
Tanno, T., Lim, Y., Wang, Q., Chesi, M., Bergsagel, P. L., Matthews, G., Johnstone, R. W., Ghosh, N., Borrello, I., Huff, C. A., et al. (2013) · Blood · doi:10.1182/blood-2013-08-524025 · Cited by 82
Macrophage Polarization in Pancreatic Carcinoma: Role of Heparanase Enzyme
Hermano, E., Meirovitz, A., Meir, K. S., Nussbaum, G., Appelbaum, L., Peretz, T., & Elkin, M. (2014) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dju332 · Cited by 81
Heparanase-enhanced Shedding of Syndecan-1 and Its Role in Driving Disease Pathogenesis and Progression
Rangarajan, S., Richter, J. R., Richter, R. P., Bandari, S., Tripathi, K. K., Vlodavsky, I., & Sanderson, R. D. (2020) · Journal of Histochemistry & Cytochemistry · doi:10.1369/0022155420937087 · Cited by 83
Self-citation
Cell surface heparan sulfate proteoglycans control adhesion and invasion of breast carcinoma cells
Lim, H. C., Multhaupt, H. A. B., & Couchman, J. (2015) · Molecular Cancer · doi:10.1186/s12943-014-0279-8 · Cited by 83
The Role of Syndecan-1 in Cellular Signaling and its Effects on Heparan Sulfate Biosynthesis in Mesenchymal Tumors
Szatmári, T., & Dobra, K. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00310 · Cited by 90
Transmembrane proteoglycans control stretch-activated channels to set cytosolic calcium levels
Gopal, S., Søgaard, P. P., Multhaupt, H. A. B., Pataki, C. A., Okina, E., Xian, X., Pedersen, M. E., Stevens, T., Griesbeck, O., Park, P. W., et al. (2015) · The Journal of Cell Biology · doi:10.1083/jcb.201501060 · Cited by 80
Proteoglycans as Mediators of Cancer Tissue Mechanics
Barkovskaya, A., Buffone, A., Žídek, M., & Weaver, V. M. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.569377 · Cited by 72
Heparanase Cooperates with Ras to Drive Breast and Skin Tumorigenesis
Boyango, I., Barash, U., Naroditsky, I., Li, J., Hammond, E., Ilan, N., & Vlodavsky, I. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2962 · Cited by 69
Self-citation
Interaction of human papillomavirus type 16 particles with heparan sulfate and syndecan-1 molecules in the keratinocyte extracellular matrix plays an active role in infection
Surviladze, Z., Sterkand, R. T., & Ozbun, M. A. (2015) · Journal of General Virology · doi:10.1099/vir.0.000147 · Cited by 70
Heparanase is a key player in renal fibrosis by regulating TGF-β expression and activity
Masola, V., Zaza, G., Secchi, M. F., Gambaro, G., Lupo, A., & Onisto, M. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2014.06.005 · Cited by 67
Chemotherapy stimulates syndecan-1 shedding: A potentially negative effect of treatment that may promote tumor relapse
Ramani, V. C., & Sanderson, R. D. (2013) · Matrix Biology · doi:10.1016/j.matbio.2013.10.005 · Cited by 66
Self-citation
Heparanase Promotes Glioma Progression and Is Inversely Correlated with Patient Survival
Kundu, S., Xiong, A., Spyrou, A., Wicher, G., Marinescu, V. D., Edqvist, P.-H. D., Zhang, L., Essand, M., Dimberg, A., Smits, A., et al. (2016) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-16-0223 · Cited by 66
Self-citation
Heparan Sulfate Mimetics in Cancer Therapy: The Challenge to Define Structural Determinants and the Relevance of Targets for Optimal Activity
Lanzi, C., & Cassinelli, G. (2018) · Molecules · doi:10.3390/molecules23112915 · Cited by 66
Heparanase Is Essential for the Development of Acute Experimental Glomerulonephritis
Garsen, M., Benner, M., Dijkman, H. B. P. M., Kuppevelt, T. H. V., Li, J., Rabelink, T. J., Vlodavsky, I., Berden, J. H. M., Rops, A. L. W. M. M., Elkin, M., et al. (2016) · American Journal Of Pathology · doi:10.1016/j.ajpath.2015.12.008 · Cited by 65
Self-citation
Mechanisms of heparanase inhibitors in cancer therapy
Heyman, B. M., & Yang, Y. (2016) · Experimental Hematology · doi:10.1016/j.exphem.2016.08.006 · Cited by 64
PG545 enhances anti-cancer activity of chemotherapy in ovarian models and increases surrogate biomarkers such as VEGF in preclinical and clinical plasma samples
Winterhoff, B. J. N., Freyer, L., Hammond, E., Giri, S., Mondal, S., Roy, D., Teoman, A., Mullany, S. A., Hoffmann, R., von Bismarck, A., et al. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.02.007 · Cited by 63
Heparin and related polysaccharides: synthesis using recombinant enzymes and metabolic engineering
Suflita, M., Fu, L., He, W., Koffas, M. A. G., & Linhardt, R. J. (2015) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-015-6821-9 · Cited by 64
The Pulmonary Endothelial Glycocalyx in ARDS: A Critical Role for Heparan Sulfate
LaRivière, W. B., & Schmidt, E. P. (2018) · Current topics in membranes · doi:10.1016/bs.ctm.2018.08.005 · Cited by 62
Micro RNA regulation of proteoglycan function in cancer
Ibrahim, S., Hassan, H., & Götte, M. (2014) · FEBS Journal · doi:10.1111/febs.13026 · Cited by 62
Heparan Sulfate Domains Required for Fibroblast Growth Factor 1 and 2 Signaling through Fibroblast Growth Factor Receptor 1c
Schultz, V. L., Suflita, M., Liu, X., Zhang, X., Yu, Y., Li, L., Green, D. E., Xu, Y., Zhang, F., DeAngelis, P. L., et al. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.761585 · Cited by 58
Heparanase: Multiple functions in inflammation, diabetes and atherosclerosis
Vlodavsky, I., Iozzo, R. V., & Sanderson, R. D. (2013) · Matrix Biology · doi:10.1016/j.matbio.2013.03.001 · Cited by 56
Self-citation
Syntenin: Key player in cancer exosome biogenesis and uptake?
Fares, J., Kashyap, R. S., & Zimmermann, P. (2016) · Cell Adhesion & Migration · doi:10.1080/19336918.2016.1225632 · Cited by 56
Recent advances in the discovery of heparanase inhibitors as anti-cancer agents
Li, J., & Ma, S. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.05.052 · Cited by 53
The CXCL12gamma chemokine immobilized by heparan sulfate on stromal niche cells controls adhesion and mediates drug resistance in multiple myeloma
Ren, Z., Lantermans, H. C., Kuil, A., Kraan, W., Arenzana‐Seisdedos, F., Kersten, M. J., Spaargaren, M., & Pals, S. T. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01031-3 · Cited by 52
Syndecans as Cell Surface Receptors in Cancer Biology. A Focus on their Interaction with PDZ Domain Proteins
Cheng, B., Montmasson, M., Terradot, L., & Rousselle, P. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00010 · Cited by 59
Proteoglycans Are Attractive Biomarkers and Therapeutic Targets in Hepatocellular Carcinoma
Tanaka, Y., Tateishi, R., & Koike, K. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19103070 · Cited by 49
The heparanase inhibitor PG545 is a potent anti-lymphoma drug: Mode of action
Weissmann, M., Bhattacharya, U., Feld, S., Hammond, E., Ilan, N., & Vlodavsky, I. (2018) · Matrix Biology · doi:10.1016/j.matbio.2018.08.005 · Cited by 48
Self-citation
Immunomodulatory activities of pixatimod: emerging nonclinical and clinical data, and its potential utility in combination with PD-1 inhibitors
Hammond, E., Haynes, N. M., Cullinane, C. M., Brennan, T. V., Bampton, D., Handley, P., Karoli, T., Lanksheer, F., Lin, L., Yang, Y., et al. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0363-5 · Cited by 48
Recent Insights into Cell Surface Heparan Sulphate Proteoglycans and Cancer
Couchman, J., Multhaupt, H. A. B., & Sanderson, R. D. (2016) · F1000Research · doi:10.12688/f1000research.8543.1 · Cited by 46
Self-citation
Syndecans in chronic inflammatory and autoimmune diseases: Pathological insights and therapeutic opportunities
Agere, S. A., Kim, E. Y., Akhtar, N., & Ahmed, S. (2017) · Journal of Cellular Physiology · doi:10.1002/jcp.26388 · Cited by 46
From Oncogenic Signaling Pathways to Single-Cell Sequencing of Immune Cells: Changing the Landscape of Cancer Immunotherapy
Derakhshani, A., Rostami, Z., Safarpour, H., Shadbad, M. A., Nourbakhsh, N. S., Argentiero, A., Taefehshokr, S., Tabrizi, N. J., Kooshkaki, O., Astamal, R. V., et al. (2021) · Molecules · doi:10.3390/molecules26082278 · Cited by 44
Elevated heparanase expression is associated with poor prognosis in breast cancer: a study based on systematic review and TCGA data
Sun, X., Zhang, G., Nian, J., Yu, M., Chen, S.-J., Zhang, Y., Yang, G., Yang, L., Cheng, P., Chen, Y., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.16575 · Cited by 42
Syndecan-1 as a Biomarker for Sepsis Survival After Major Abdominal Surgery
Holzmann, M., Winkler, M. S., Strunden, M. S., Izbicki, J. R., Schoen, G., Greiwe, G., Pinnschmidt, H. O., Poppe, A., Saugel, B., Daum, G., et al. (2018) · Biomarkers in Medicine · doi:10.2217/bmm-2017-0231 · Cited by 43
Soluble syndecan‐1 (SDC1) serum level as an independent pre‐operative predictor of cancer‐specific survival in prostate cancer
Szarvas, T., Reis, H., Dorp, F. V., Tschirdewahn, S., Niedworok, C., Nyírády, P., Schmid, K. W., Rubben, H., & Kovalszky, I. (2016) · The Prostate · doi:10.1002/pros.23186 · Cited by 41
Mining of potential microRNAs with clinical correlation - regulation of syndecan-1 expression by miR-122-5p altered mobility of breast cancer cells and possible correlation with liver injury
Uen, Y., Wang, J.-W., Wang, C., Jhang, Y., Chung, J.-Y., Tseng, T., Sheu, M., & Lee, S.-C. (2018) · Oncotarget · doi:10.18632/oncotarget.25589 · Cited by 41
MicroRNA-143 Targets Syndecan-1 to Repress Cell Growth in Melanoma
Li, R., Zhang, L., Jia, L., Duan, Y., Li, Y., Wang, J., Bao, L., & Sha, N. (2014) · PLoS ONE · doi:10.1371/journal.pone.0094855 · Cited by 39
Retracted
Nuclear translocation of heparan sulfate proteoglycans and their functional significance
Kovalszky, I., Hjerpe, A., & Dobra, K. (2014) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2014.04.015 · Cited by 38
Heparan Sulfate Glycosaminoglycans: (Un)Expected Allies in Cancer Clinical Management
Faria‐Ramos, I., Poças, J., Marques, C., Santos‐Antunes, J., Macedo, G., Reis, C. A., & Magalhães, A. (2021) · Biomolecules · doi:10.3390/biom11020136 · Cited by 39
Low molecular weight heparin tinzaparin antagonizes cisplatin resistance of ovarian cancer cells
Pfankuchen, D. B., Stölting, D. P., Schlesinger, M., Royer, H., & Bendas, G. (2015) · Biochemical Pharmacology · doi:10.1016/j.bcp.2015.07.013 · Cited by 37
Upregulated Expression of Heparanase in the Vitreous of Patients With Proliferative Diabetic Retinopathy Originates From Activated Endothelial Cells and Leukocytes
El‐Asrar, A. M. A., Alam, K., Nawaz, M. I., Mohammad, G., den Eynde, K. V., Siddiquei, M. M., Mousa, A., Hertogh, G. D., Geboes, K. J., & Opdenakker, G. (2015) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.15-18025 · Cited by 37
Heparanase promotes myeloma stemness and in vivo tumorigenesis
Tripathi, K. K., Ramani, V. C., Bandari, S., Amin, R., Brown, E. E., Ritchie, J. P., Stewart, M. D., & Sanderson, R. D. (2019) · Matrix Biology · doi:10.1016/j.matbio.2019.11.004 · Cited by 37
Self-citation
Involvement of Syndecan-1 and Heparanase in Cancer and Inflammation
Teixeira, F. C. O. B., & Götte, M. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-34521-1_4 · Cited by 38
Circulating Heparan Sulfate Proteoglycans as Biomarkers in Health and Disease
Lepedda, A. J., Nieddu, G., Piperigkou, Z., Kyriakopoulou, K., Karamanos, N. K., & Formato, M. (2021) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0041-1725063 · Cited by 38
MicroRNA-dependent targeting of the extracellular matrix as a mechanism of regulating cell behavior
Ibrahim, S., Hassan, H., & Götte, M. (2014) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2014.01.022 · Cited by 37
Heparanase as a Target in Cancer Therapy
Masola, V., Secchi, M. F., Gambaro, G., & Onisto, M. (2014) · Current Cancer Drug Targets · doi:10.2174/1568009614666140224155124 · Cited by 36
MYCN promotes neuroblastoma malignancy by establishing a regulatory circuit with transcription factor AP4
Xue, C., Yu, D. M. T., Gherardi, S., Koach, J., Milazzo, G., Gamble, L. D., Liu, B., Valli, E., Russell, A. J., London, W. B., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.10709 · Cited by 36
The Role and Therapeutic Value of Syndecan-1 in Cancer Metastasis and Drug Resistance
Guo, S., Wu, X., Lei, T., Zhong, R., Wang, Y., Zhang, L. N., Zhao, Q., Huang, Y., Shi, Y., & Wu, L. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.784983 · Cited by 35
Heparan sulfate inhibitors and their therapeutic implications in inflammatory illnesses
Ferro, V. (2013) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2013.811491 · Cited by 35
Diagnostic and Prognostic Value of Soluble Syndecan-1 in Pleural Malignancies
Mundt, F., Heidari-Hamedani, G., Nilsonne, G., Metintaş, M., Hjerpe, A., & Dobra, K. (2014) · BioMed Research International · doi:10.1155/2014/419853 · Cited by 34
Heparanase-1-induced shedding of heparan sulfate from syndecan-1 in hepatocarcinoma cell facilitates lymphatic endothelial cell proliferation via VEGF-C/ERK pathway
Yu, S., Lv, H., Zhang, H., Jiang, Y., Hong, Y. H., Xia, R., Zhang, Q., Ju, W., Jiang, L., Ou, G., et al. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.02.060 · Cited by 34
A Liquid Chromatography-Mass Spectrometry-based Approach to Characterize the Substrate Specificity of Mammalian Heparanase
Mao, Y., Huang, Y., Buczek‐Thomas, J. A., Ethen, C. M., Nugent, M. A., Wu, Z. L., & Zaia, J. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.589630 · Cited by 33
Extracellular matrix alterations in the skin of patients affected by psoriasis
Wagner, M. F. M. G., Theodoro, T. R., Filho, C. D. S. M., Oyafuso, L. K. M., & Pinhal, M. A. D. S. (2021) · BMC Molecular and Cell Biology · doi:10.1186/s12860-021-00395-1 · Cited by 33
Cancer biology in diabetes
Shi, S., He, Y., Koya, D., & Kanasaki, K. (2014) · Journal of Diabetes Investigation · doi:10.1111/jdi.12208 · Cited by 33
Heparanase: A Dynamic Promoter of Myeloma Progression
Purushothaman, A., & Sanderson, R. D. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-34521-1_12 · Cited by 31
Self-citation
Syndecan-1 and stromal heparan sulfate proteoglycans: key moderators of plasma cell biology and myeloma pathogenesis
Ren, Z., Spaargaren, M., & Pals, S. T. (2021) · Blood · doi:10.1182/blood.2020008188 · Cited by 32
Prognostic and clinical significance of syndecan-1 in colorectal cancer: a meta-analysis
Wei, H., Guo, E.-N., Dong, B.-G., & Chen, L. (2015) · BMC Gastroenterology · doi:10.1186/s12876-015-0383-2 · Cited by 31
Hepatocyte Growth Factor and Satellite Cell Activation
Anderson, J. E. (2016) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-27511-6_1 · Cited by 30
Emerging Role of Syndecans in Extracellular Matrix Remodeling in Cancer
Jang, B., Kim, A., Hwang, J., Song, H.-K., Kim, Y., & Oh, E. (2020) · Journal of Histochemistry & Cytochemistry · doi:10.1369/0022155420930112 · Cited by 29

Authors: Ramani, V. C., Purushothaman, A., Stewart, M. D., Thompson, C. A., Vlodavsky, I., Au, J. L., & Sanderson, R. D.
Affiliations: University of Alabama at Birmingham (US)
Cancer and Vascular Biology Research Center Rappaport Faculty of Medicine Haifa Israel
Optimum Therapeutics (United States) (US)
Corresponding author: Sanderson, Ralph D.
ORCID: Ramani, Vishnu C.
Purushothaman, Anurag
Stewart, Mark D.
Au, Jessie L‐S.
Sanderson, Ralph D.
Venue: The FEBS Journal
Publisher: Wiley
Published: 2013-03-04
Volume: 280
Issue: 10
Pages: 2294-2306
ISSN: 1742-464X (ISSN-L)
1742-4658
DOI: 10.1111/febs.12168
PMC: PMC3651779
OpenAlex: W2104368170
Cited by: 189
References: 115
Citations by year: 2026: 7 · 2025: 2 · 2024: 5 · 2023: 9 · 2022: 16 · 2021: 17 · 2020: 18 · 2019: 8 · 2018: 12 · 2017: 11 · 2016: 30 · 2015: 21 · 2014: 24 · 2013: 9
FWCI: 3.22
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: onlinelibrary.wiley.com/termsAndConditions#vor (vor)
Locations: FEBS Journal (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: National Institutes of Health
National Cancer Institute (CA135075, CA138340, R01CA138340, CA138535, R01CA135075, R01CA138535)
National Institute of General Medical Sciences (T32GM008111)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Proteoglycans and glycosaminoglycans research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Protease and Inhibitor Mechanisms
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
Keywords: heparanase, syndecan-1, heparan sulfate proteoglycans, cancer, growth factor signaling, tumor growth, metastasis, angiogenesis, osteolysis, heparanase inhibitors
MeSH terms: Heparanase, Animals, Antineoplastic Agents, Cell Nucleus, Enzyme Activation, Enzyme Inhibitors, Glucuronidase, Heparitin Sulfate, Heparan Sulfate, Humans, Neoplasms, Signal Transduction, Gene Expression Regulation, Neoplastic, Hepatocyte Growth Factor, Biomimetic Materials, Syndecan-1, Exosomes

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

The heparanase/syndecan‐1 axis in cancer: mechanisms and therapies

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks